Inclusion Criteria:  Age ≥ 18 years R/R T-NHL with measurable (≧1.5cm) lesions confirmed by pathological immunohistochemistry or flow cytometry The expressions of both CD4 and CD8 are negative in patients with bone marrow involved The Eastern Cooperative Oncoloy Group (ECOG) physical condition score ≤ 2 points  The main organ functions need to meet the following conditions:  A.Left ventricular ejection fraction ≥50% B.Creatinine ≤132umol/l or creatinine clearance ≥60 ml/min C.ALT and AST≤2.5 upper limitation of normal D.T-BIL≤2.0mg/dl E.SpO2 > 90%  Results of pregnant test should be negative, and agree to conception control during treatment and 1 year after CAR-T infusion Expected survival exceeds 3 months Written informed consent could be acquired  Exclusion Criteria:  Immunosuppressant medications or steroids were used within 2 weeks before cell collection, or need to use steroids or immunosuppressant medications more than two years Patients with uncontrolled active infection Active hepatitis B or hepatitis C infection Patients with HIV infection Severe acute or chronic graft-versus-host disease (GVHD) Participated in any other drug research clinical trials within 30 days before enrollment Prior CAR-T cells therapy within 3 months before enrollment Prior allogeneic hematopoietic stem cell transplantation within 6 months before enrollment Uncontrolled other tumor Women in pregnancy, lactation or planning to become pregnant The researcher considers inappropriate to participate in this research